Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
1.820
-0.065 (-3.45%)
Feb 5, 2026, 2:08 PM EST - Market open
Lyra Therapeutics Employees
Lyra Therapeutics had 30 employees as of December 31, 2024. The number of employees decreased by 58 or -65.91% compared to the previous year.
Employees
30
Change
-58
Growth
-65.91%
Revenue / Employee
$20,000
Profits / Employee
-$1,098,233
Market Cap
3.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 30 | -58 | -65.91% |
| Mar 31, 2024 | 109 | 45 | 70.31% |
| Dec 31, 2023 | 88 | 30 | 51.72% |
| Sep 30, 2023 | 78 | 19 | 32.20% |
| Jun 30, 2023 | 73 | 13 | 21.67% |
| Mar 31, 2023 | 64 | 7 | 12.28% |
| Dec 31, 2022 | 58 | 5 | 9.43% |
| Sep 30, 2022 | 59 | 5 | 9.26% |
| Jun 30, 2022 | 60 | 15 | 33.33% |
| Mar 31, 2022 | 57 | 14 | 32.56% |
| Dec 31, 2021 | 53 | 15 | 39.47% |
| Sep 30, 2021 | 54 | 21 | 63.64% |
| Jun 30, 2021 | 45 | 14 | 45.16% |
| Mar 31, 2021 | 43 | 9 | 26.47% |
| Dec 31, 2020 | 38 | 0 | - |
| Sep 30, 2020 | 33 | -5 | -13.16% |
| Jun 30, 2020 | 31 | - | - |
| Mar 31, 2020 | 34 | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Galmed Pharmaceuticals | 6 |
| CNS Pharmaceuticals | 5 |
| Oragenics | 5 |
| Artelo Biosciences | 5 |
| XORTX Therapeutics | 3 |
| Matinas BioPharma Holdings | 3 |
LYRA News
- 24 days ago - Lyra Therapeutics Provides Corporate Update - GlobeNewsWire
- 3 months ago - Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - GlobeNewsWire
- 6 months ago - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 8 months ago - Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
- 8 months ago - Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
- 8 months ago - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewsWire